Vericel Corp (NAS:VCEL)
$ 57.31 0.27 (0.47%) Market Cap: 2.83 Bil Enterprise Value: 2.82 Bil PE Ratio: 818.71 PB Ratio: 10.96 GF Score: 79/100

Vericel Corp at UBS Global Healthcare Conference Transcript

May 22, 2019 / 02:30PM GMT
Release Date Price: $15.71 (-0.44%)
Unidentified Analyst

Okay. Thanks, everybody, for joining us. For our next session, we're joined by management from Vericel. So behind me is Nick Colangelo, who is the President and CEO. And he's going to go through a slide presentation. And if we have any time at the end, we'll do a little bit of Q&A, but we're going to have a breakout downstairs.

So let me turn it over to you, Nick. Take it away.

Dominick C. Colangelo
Vericel Corporation - CEO, President & Director

Okay. Well, thanks. It's great to be here for the first time at the UBS conference. So we appreciate the invitation.

So before I begin, I'd like to remind you that this presentation contains forward-looking statements. Hence, you should refer to our documents on file with the SEC for further information.

So Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. We have a highly innovative, advanced cell therapy platform, and our strategy has been to build our commercial franchises around our cell therapy products in our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot